|
1
|
Lièvre A, Bachet JB, Le Corre D, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benvenuti S, Sartore-Bianchi A, Di
Nicolantonio F, et al: Oncogenic activation of the RAS/RAF
signaling pathway impairs the response of metastatic colorectal
cancers to anti-epidermal growth factor receptor antibody
therapies. Cancer Res. 67:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amado RG, Wolf M, Peeters M, et al:
Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sartore-Bianchi A, Di Nicolantonio F,
Nichelatti M, et al: Multi-determinants analysis of molecular
alterations for predicting clinical benefit to EGFR-targeted
monoclonal antibodies in colorectal cancer. PLoS One. 4:e72872009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Di Nicolantonio F, Martini M, Molinari F,
et al: Wild-type BRAF is required for response to panitumumab or
cetuximab in metastatic colorectal cancer. J Clin Oncol.
26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Frattini M, Saletti P, Romagnani E, et al:
PTEN loss of expression predicts cetuximab efficacy in metastatic
colorectal cancer patients. Br J Cancer. 97:1139–1145. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perrone F, Lampis A, Orsenigo M, et al:
PI3KCA/PTEN deregulation contributes to impaired responses to
cetuximab in metastatic colorectal cancer patients. Ann Oncol.
20:84–90. 2009. View Article : Google Scholar
|
|
8
|
Sartore-Bianchi A, Martini M, Molinari F,
et al: PIK3CA mutations in colorectal cancer are associated with
clinical resistance to EGFR-targeted monoclonal antibodies. Cancer
Res. 69:1851–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jhawer M, Goel S, Wilson AJ, et al: PIK3CA
mutation/PTEN expression status predicts response of colon cancer
cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer Res. 68:1953–1961. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Laurent-Puig P, Cayre A, Manceau G, et al:
Analysis of PTEN, BRAF, and EGFR status in determining benefit from
cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin
Oncol. 27:5924–5930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Razis E, Briasoulis E, Vrettou E, et al:
Potential value of PTEN in predicting cetuximab response in
colorectal cancer: An exploratory study. BMC Cancer. 8:2342008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ulivi P, Capelli L, Valgiusti M, et al:
Predictive role of multiple gene alterations in response to
cetuximab in metastatic colorectal cancer: A single center study. J
Transl Med. 10:872012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van Cutsem E, Köhne CH, Láng I, et al:
Cetuximab plus irinotecan, fluorouracil, and leucovorin as
first-line treatment for metastatic colorectal cancer: Updated
analysis of overall survival according to tumor KRAS and BRAF
mutation status. J Clin Oncol. 29:2011–2019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ogino S, Nosho K, Kirkner GJ, et al: CpG
island methylator phenotype, microsatellite instability, BRAF
mutation and clinical outcome in colon cancer. Gut. 58:90–96. 2009.
View Article : Google Scholar :
|
|
15
|
Tol J, Nagtegaal ID and Punt CJ: BRAF
mutation in metastatic colorectal cancer. N Engl J Med. 361:98–99.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ogino S, Nosho K, Kirkner GJ, et al:
PIK3CA mutation is associated with poor prognosis among patients
with curatively resected colon cancer. J Clin Oncol. 27:1477–1484.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Valentini AM, Pirrelli M and Caruso ML:
EGFR-targeted therapy in colorectal cancer: Does
immunohistochemistry deserve a role in predicting the response to
cetuximab? Curr Opin Mol Ther. 10:124–131. 2008.PubMed/NCBI
|
|
19
|
Scartozzi M, Bearzi I, Mandolesi A, et al:
Epidermal growth factor receptor (EGFR) gene promoter methylation
and cetuximab treatment in colorectal cancer patients. Br J Cancer.
104:1786–1790. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
National Cancer Institute. Cancer Therapy
Evaluation Program, Common Terminology Criteria for Adverse Events,
Version 3.0. http://ctep.cancer.gov.
Accessed December 17, 2013
|
|
22
|
De Roock W, Claes B, Bernasconi D, et al:
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy
of cetuximab plus chemotherapy in chemotherapy-refractory
metastatic colorectal cancer: A retrospective consortium analysis.
Lancet Oncol. 11:753–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cunningham D, Humblet Y, Siena S, et al:
Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scartozzi M, Bearzi I, Mandolesi A, et al:
Epidermal growth factor receptor (EGFR) gene copy number (GCN)
correlates with clinical activity of irinotecan-cetuximab in K-RAS
wild-type colorectal cancer: A fluorescence in situ (FISH) and
chromogenic in situ hybridization (CISH) analysis. BMC Cancer.
9:3032009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Licitra L, Störkel S, Kerr KM, et al:
Predictive value of epidermal growth factor receptor expression for
first-line chemotherapy plus cetuximab in patients with head and
neck and colorectal cancer: Analysis of data from the EXTREME and
CRYSTAL studies. Eur J Cancer. 49:1161–1168. 2013. View Article : Google Scholar
|
|
26
|
Atkins D, Reiffen KA, Tegtmeier CL,
Winther H, Bonato MS and Störkel S: Immunohistochemical detection
of EGFR in paraffin-embedded tumor tissues: Variation in staining
intensity due to choice of fixative and storage time of tissue
sections. J Histochem Cytochem. 52:893–901. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Montero AJ, Díaz-Montero CM, Mao L,
Youssef EM, Estecio M, Shen L and Issa JP: Epigenetic inactivation
of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther.
5:1494–1501. 2006. View Article : Google Scholar
|
